Moira Capital Acquires 45.5% of Biorizon Biotech, World Leader in Biopesticides

Moira Capital Partners has acquired 45.5% of Biorizon Biotech, a world leader in biostimulants and biopesticides based on microalgae. The fund led by Javier Loizaga will inject $11.3 million (€10 million) in the Almeria-based company to boost its growth, while the rest of the shares will remain in the hands of the management team and the founding partners.

With its entry into Biorizon Biotech, Moira Capital Partners has 12 companies in its portfolio with a total disbursement of $181 million (€160 million), promoting high-growth projects and consolidating the model initiated more than four years ago. The fund manager invests in innovative companies seeking to undertake high-growth projects in the medium and long term, with a differentiated approach that allows high returns on investment.

Read more on the subject and find the latest business headlines with the Born2Invest mobile app.

Biorizon Biotech’s international expansion

Biorizon Biotech will invest $26 million (€23 million) in product registrations in strategic markets and will optimize its microalgae and cyanobacteria production plant, the largest in Europe, located in Almería. With a presence in seven countries, Spain, Italy, Portugal, Peru, China, Ecuador, Chile, and Morocco, the company will continue to promote its internationalization in southern Europe, Latin America, and Asia.

Sebastián Cerezo, partner at Moira Capital, explained that “Biorizon Biotech represents a unique investment opportunity in the emerging and growing sector of biostimulants and bioprotectors for agricultural application, with one of the world leaders in terms of R&D, production capabilities and product range, with a profitable and scalable platform, and a first-class management team.” For his part, David Iglesias, CEO of Biorizon Biotech, highlighted that “Moira is the ideal partner to drive our ambitious business plan. His proven experience in expansion processes of technology companies makes him the best possible traveling companion for our company, which has been investing around 30% of its turnover in R&D.”

Founded in 2010 in Almeria by its CEO David Iglesias, together with Joaquín Pozo, R&D&I director, and Fernando Román, marketing and communication director, Biorizon Biotech has positioned itself as one of the most innovative operators in integral solutions for agricultural needs, taking advantage of the global need to increase food production, increase crop yields and the impulse of new regulations that prioritize sustainability criteria.

High-return investments for Moira Capital

Moira Capital, based in Madrid, started its activity in early 2017 as a manager specialized in direct high-return investments for private investors and institutions. The private equity manager leads investments of between 5 and 100 million in capital, under a differential approach with respect to traditional private equity, which allows it to access unique and exclusive investment opportunities, financing each operation hand in hand with a club of families and institutions.

In just over four years, it has committed more than 160 million to boost the high-growth projects of 12 innovative Spanish companies: Biorizon Biotech itself; Cella Medical Solutions, a leader in complex medical technologies; Voovio, a simulation and virtual reality company applied to the process industry; logistics operator GOI; Cubiq, a pioneer in healthy fats; Grit, a leader in the liquefied and liquid specialty gases sector; Bioflytech, pioneers in the production and commercialization of insect protein and fat for fish and pet food; Euroespes, a benchmark company in genomic medicine; Greene, gasification technology for waste recovery; Sipay, a payment service provider; Eskariam, an innovative platform for class action management; and the dermatology clinic Pedro Jaén.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elEconomista.es, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.